Studying the success of three different drug regimens in eradicating Helicobacter pylori infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240730062592N1

Enrollment

150

Registered

2025-02-28

Start date

2024-08-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: Group B (intervention group 1) received the standard regimen including levofloxacin 500 mg once a day + amoxicillin 1 g twice a day + omeprazole 20 mg twice a day f

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Consent to participate in the study Being positive for Helicobacter pylori infection Age 18-60 years

Exclusion criteria

Exclusion criteria: pregnant breast-feeding History of gastric surgery Antibiotics taken within the past month Allergy to any of the drugs used in the study Chronic Kidney Disease (CKD) (stages 4 and 5)

Design outcomes

Primary

Measure	Time frame
The effectiveness of the drug (eradication of Helicobacter pylori infection). Timepoint: Four weeks after the treatment, the patients are called again and they are evaluated for the eradication of Helicobacter pylori by Helicobacter pylori stool antigen test. Method of measurement: Comparing the effects of triple-drug regimens on eradication of Helicobacter pylori infection.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMobina Zamanifard

Arak University of Medical Sciences

dr.mobina.zamanifard@gmail.com+98 81 3224 0525

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026